Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive of Clinical Outcome in Primary Central Nervous System Lymphoma

References

1. 1.↵
   Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Hinsdale, Ilinois: Central Brain Tumor Registry of the United States; 2005
2. 2.↵
   1. Surawicz TS,
   2. McCarthy BJ,
   3. Kupelian V,
   4. et al

   . Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999; 1: 14–25

   Abstract/FREE Full Text
3. 3.↵
   1. Olson JE,
   2. Janney CA,
   3. Rao RD,
   4. et al

   . The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95: 1504–10

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Hochberg F,
   2. Baehring J,
   3. Hochberg E

   . Primary CNS lymphoma. Nat Clin Pract Neurol 2007; 3: 24–35

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Abrey LE,
   2. Batchelor TT,
   3. Ferreri AJ,
   4. et al.,
   5. for the International Primary CNS Lymphoma Collaborative Group

   . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–43. Epub 2005 Jun 13

   Abstract/FREE Full Text
6. 6.↵
   1. Glass J,
   2. Gruber ML,
   3. Cher L,
   4. et al

   . Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188–95

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Gavrilovic IT,
   2. Hormigo A,
   3. Yahalom J,
   4. et al

   . Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 28: 4570–74
8. 8.↵
   1. Abrey LE,
   2. DeAngelis LM,
   3. Yahalom J

   . Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–63

   Abstract
9. 9.↵
   1. Rubenstein JL,
   2. Fridlyand J,
   3. Abrey L,
   4. et al

   . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350–56. Epub 2007 Feb 20

   Abstract/FREE Full Text
10. 10.↵
    1. Soussain C,
    2. Hoang-Xuan K,
    3. Taillandier L,
    4. et al

    . Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma. J Clin Oncol 2008; 26: 2512–18

    Abstract/FREE Full Text
11. 11.↵
    1. Le Bihan D,
    2. Turner R,
    3. Douek P,
    4. et al

    . Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992; 159: 591–99

    PubMedWeb of Science
12. 12.↵
    1. Rowley HA,
    2. Grant PE,
    3. Roberts TP

    . Diffusion MR imaging: theory and applications. Neuroimaging Clin N Am 1999; 9: 343–61

    PubMedWeb of Science
13. 13.↵
    1. Le Bihan D,
    2. Breton E,
    3. Lallemand D,
    4. et al

    . MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401–07

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Guo AC,
    2. Cummings TJ,
    3. Dash RC,
    4. et al

    . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002; 224: 177–83

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Rubenstein J,
    2. Shen A,
    3. Batchelor T,
    4. et al

    . Differential gene expression in central nervous system lymphoma. Blood 2009; 113: 266–67

    FREE Full Text
16. 16.↵
    1. Rubenstein J,
    2. Fridlyand J,
    3. Shen A,
    4. et al

    . Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107: 3716–23

    Abstract/FREE Full Text
17. 17.↵
    1. Blay JY,
    2. Conroy T,
    3. Chevreau C,
    4. et al

    . High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864–71

    Abstract
18. 18.↵
    1. Burger PC,
    2. Shibata T,
    3. Kleihues P

    . The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986; 10: 611–17

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Matsumoto Y,
    2. Horiike S,
    3. Fujimoto Y,
    4. et al

    . Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol 2007; 85: 333–37

    CrossRefPubMed
20. 20.↵
    1. Ryken TC,
    2. Meeks SL,
    3. Pennington EC,
    4. et al

    . Initial clinical experience with frameless stereotactic radiosurgery: analysis of accuracy and feasibility. Int J Radiat Oncol Biol Phys 2001; 51: 1152–58

    PubMed
21. 21.↵
    1. Roy S,
    2. Josephson SA,
    3. Fridlyand J,
    4. et al

    . Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008; 26: 96–105

    Abstract/FREE Full Text
22. 22.↵
    1. Ducreux D,
    2. Wu RH,
    3. Mikulis DJ,
    4. et al

    . Diffusion-weighted imaging and single-voxel MR spectroscopy in a case of malignant cerebral lymphoma. Neuroradiology 2003; 45: 865–68

    CrossRefPubMed
23. 23.↵
    1. Stadnik TW,
    2. Chaskis C,
    3. Michotte A,
    4. et al

    . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001; 22: 969–76

    Abstract/FREE Full Text
24. 24.↵
    1. Kitis O,
    2. Altay H,
    3. Calli C,
    4. et al

    . Minimum apparent diffusion coefficients in the evaluation of brain tumors. Euro J Radiol 2005; 55: 393–400

    CrossRef
25. 25.↵
    1. Reiche W,
    2. Hagen T,
    3. Schuchardt V,
    4. et al

    . Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas: a report of four cases with common and uncommon imaging features. Clin Neurol Neurosurg 2007; 109: 92–101

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Toh CH,
    2. Castillo M,
    3. Wong AM,
    4. et al

    . Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008; 29: 471–75

    Abstract/FREE Full Text
27. 27.↵
    1. O’Neill BP,
    2. Kelly PJ,
    3. Earle JD,
    4. et al

    . Computer-assisted stereotaxic biopsy for the diagnosis of primary central nervous system lymphoma. Neurology 1987; 37: 1160–64

    Abstract/FREE Full Text
28. 28.↵
    1. Murray K,
    2. Kun L,
    3. Cox J

    . Primary malignant lymphoma of the central nervous system, result of treatment of 11 cases and review of the literature. J Neursosurg 1986; 65: 600–07

    CrossRef
29. 29.↵
    1. O’Neill BP,
    2. Illig JJ

    . Primary central nervous system lymphoma. Mayo Clin Proc 1989; 64: 1005–20

    CrossRefPubMedWeb of Science
30. 30.↵
    1. McAllister LD,
    2. Doolittle ND,
    3. Guastadisegni PE,
    4. et al

    . Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51–61

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Moffat BA,
    2. Chenevert TL,
    3. Lawrence TS,
    4. et al

    . Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005; 102: 5524–29

    Abstract/FREE Full Text
32. 32.↵
    1. Chenevert TL,
    2. Stegman LD,
    3. Taylor JM,
    4. et al

    . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029–36

    Abstract/FREE Full Text
33. 33.↵
    1. Mardor Y,
    2. Pfeffer R,
    3. Spiegelmann R,
    4. et al

    . Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003; 21: 1094–100

    Abstract/FREE Full Text
34. 34.↵
    1. Hamstra DA,
    2. Chenevert TL,
    3. Moffat BA,
    4. et al

    . Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102: 16759–64

    Abstract/FREE Full Text